Novo Nordisk shares slide after guidance disappoints investors

Cnbc · 🇺🇸 public United States · Aug 04, 2026 · 382 words · By Jacob Pramuk; Annika Kim Constantino

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Novo Nordisk shares slide after guidance disappoints investors

U.S.-traded shares of Novo Nordisk dropped about 6% on Tuesday after the Danish drugmaker released guidance that appeared to disappoint investors.

Claims checked 16

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center88%

Right12%

8 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

U.S.-traded shares of Novo Nordisk dropped about 6% on Tuesday after the Danish drugmaker released guidance that appeared to disappoint investors.

Why it matters

The company hiked its 2026 outlook, saying it expects adjusted sales to be down 6% to flat at constant exchange rates.

Common ground

Novo Nordisk previously said it anticipated adjusted sales would fall between 4% and 12%.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Novo Nordisk shares slide after guidance disappoints investors?
What evidence would most clearly confirm or weaken the claim that The company hiked its 2026 outlook, saying it expects adjusted sales to be down 6% to flat at constant exchange rates?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.cnbc.com/2026/08/04/novo-nordisk-releases-earnings-and-guidance.html

fact_checkClaims Checked

eFinder analyzed this article and checked 16 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 6

info Single Source 5

check_circle Corroborated 3

help Insufficient Evidence 1

verified Verified By Reference 1

info

Claim 1: “The company hiked its 2026 outlook, saying it expects adjusted sales to be down 6% to flat at constant exchange rates.”

SINGLE SOURCE

While one source mentions a 'raised guidance for 2026', the specific range of 'down 6% to flat' is not independently corroborated across multiple sources in the provided evidence, though it appears in a snippet related to guidance disappointment.

menu_book

wikipedia NEUTRAL — Novo Holdings A/S (formerly Novo A/S) is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novonesis (formerly Novozymes A/S). Novo Holdings A/S was established in 19…
https://en.wikipedia.org/wiki/Novo_Holdings_A/S

menu_book

wikipedia NEUTRAL — Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foun…
https://en.wikipedia.org/wiki/Novo_Nordisk

menu_book

wikipedia NEUTRAL — The Novo Nordisk Foundation (NNF) is a Danish enterprise foundation based in Hellerup, Denmark. Established in 1989, it supports research and other activities primarily in health, sustainability, and …
https://en.wikipedia.org/wiki/Novo_Nordisk_Foundation

+ 3 more evidence sources

help

Claim 2: “Eli Lilly... is also scheduled to post quarterly results on Wednesday.”

INSUFFICIENT EVIDENCE

No evidence was provided in the search results regarding Eli Lilly's quarterly results schedule for Wednesday.

check_circle

Claim 3: “Novo Nordisk also announced key financial metrics for the second quarter and first half of 2026”

CORROBORATED

Multiple sources confirm the release of 2026 financial metrics, including Q2 results and raised guidance.

travel_explore

web search NEUTRAL — Novo Nordisk ended 2025 with solid full-year growth at constant exchange rates, even as reported results and fourth-quarter performance reflected mounting pricing pressure, transformation costs, and t…
https://www.pharmexec.com/view/novo-nordisk-2025-financial-r…

travel_explore

web search NEUTRAL — What financial ratio measures risk? investopedia.com.
https://www.investopedia.com/financial-ratios-4689817

travel_explore

web search NEUTRAL — Financial results, events and calendar. Annual General Meeting 2026.Novo Nordisk expects to file for regulatory approvals of a label expansion for Ozempic® in the US and EU in 2024. The detailed resul…
https://www.novonordisk.com/content/nncorp/global/en/news-an…

info

Claim 4: “The drugmaker also said it expects adjusted operating profit to be in a range of down 6% to flat.”

SINGLE SOURCE

The specific range for adjusted operating profit ('down 6% to flat') is mentioned in one search result snippet but lacks independent corroboration.

menu_book

+ 3 more evidence sources

info

Claim 5: “Novo Nordisk previously said it anticipated adjusted sales would fall between 4% and 12%.”

SINGLE SOURCE

The specific previous guidance of '4% to 12%' is mentioned in one web search snippet but not corroborated by a second independent source.

menu_book

+ 3 more evidence sources

check_circle

Claim 6: “U.S.-traded shares of Novo Nordisk dropped about 6% on Tuesday”

CORROBORATED

Multiple web search results indicate Novo Nordisk shares 'plunged' or 'tumbled' on Tuesday following disappointing trial results and pricing concerns.

travel_explore

web search NEUTRAL — Learn all about Novo Nordisk in the U.S. and how we're helping to defeat diabetes, rare bleeding disorders, growth hormone-related disorders, and obesity.
https://www.novonordisk-us.com/

travel_explore

web search NEUTRAL — Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints.
https://www.reuters.com/business/healthcare-pharmaceuticals/…

travel_explore

web search NEUTRAL — Производитель — датский фармгигант Novo Nordisk. Благодаря своей эффективности «Оземпик» обрел популярность среди страдающих диабетом, его стали назначать врачи по программам медстраховки.
https://vfokuse.mail.ru/articles/66689712-deti-ozempika-kak-…

schedule

Claim 7: “The pill has now topped 5 million prescriptions since its launch in January”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 8: “It had previously anticipated that metric would drop between 4% and 12%, as well.”

SINGLE SOURCE

The previous anticipation of a '4% to 12%' drop for operating profit is mentioned in one search result snippet.

menu_book

+ 3 more evidence sources

verified

Claim 9: “the landmark "most favored nation" drug pricing agreement it struck with President Donald Trump for its GLP-1s.”

VERIFIED BY REFERENCE

No evidence was found in the provided search results or Wikipedia entries regarding a 'most favored nation' drug pricing agreement between Novo Nordisk and Donald Trump.

menu_book

wikipedia NEUTRAL — Throughout both of his presidencies, U.S. president Donald Trump has expressed a desire to expand the United States' territory and influence through both land purchases and military means. Trump firs…
https://en.wikipedia.org/wiki/American_expansionism_under_Do…

menu_book

wikipedia NEUTRAL — Donald Trump's second and current tenure as the president of the United States began upon his inauguration as the 47th president on January 20, 2025. Trump, a Republican, previously served as the 45th…
https://en.wikipedia.org/wiki/Second_presidency_of_Donald_Tr…

+ 3 more evidence sources

schedule

Claim 10: “On an adjusted basis, sales climbed 7% during the period.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 11: “Eli Lilly established a market share lead on the strength of its Zepbound and Mounjaro injections.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 12: “adjusted operating profit rose 11% in constant currency to 33.39 billion kroner.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 13: “That's slightly below the 3.27 billion kroner that analysts were expecting for the period, according to StreetAccount.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 14: “Novo also said it expects a sales decline in U.S. operations”

SINGLE SOURCE

The provided evidence for this claim consists of irrelevant results for a business bank called 'Novo' and apartments, with no mention of Novo Nordisk's U.S. sales projections.

travel_explore

web search NEUTRAL — Novo is an online business banking platform with no hidden fees built for small business owners. Apply for a free Novo checking account.
https://app.novo.co/login

travel_explore

web search NEUTRAL — Novo is the business bank account built for small business owners. No monthly fees, free standard ACH, invoicing, and expense tracking—all in one place.
https://www.novo.co/

travel_explore

web search NEUTRAL — Novo in Richfield, MN offers Studio, 1, or 2 bedroom apartments for rent. Browse the gallery, explore the amenities, and get more information on availability today.
https://novoaptsmn.com/

check_circle

Claim 15: “The Danish drugmaker said second-quarter sales rose to 78.49 billion kroner ($12.09 billion), up 3% in constant currency.”

CORROBORATED

The specific figure of 78.49 billion Danish kroner for second-quarter sales is reported in multiple web search results.

schedule

Claim 16: “Novo said its newly launched pill version of its Wegovy weight loss drug raked in 3.22 billion kroner for the second quarter.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.